1204 completed, 112 unknown, 101 terminated, 47 withdrawn. 1558 Phase 3, 160 Phase 2.
Follow Communicable Diseases: new trials by email Literature Review of Communicable Diseases trials Research Report on Communicable Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children Zopapogene imadenovec-drba - Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis | Phase 3 | Not yet recruiting | Precigen, Inc | 15 | 2026-12-31 | 2026-10-28 |
| A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women Doxycycline hyclate, Standard of Care for STI prevention - Sexually Transmitted Infection (STI), Gonorrhea | Phase 3 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 580 | 2026-11-30 | 2026-10-20 |
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| Naproxen Versus Placebo as Adjunct Treatment of Cellulitis enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious | Phase 3 | Not yet recruiting | Ottawa Hospital Research Institute | 884 | 2026-11-01 | 2026-10-20 |
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Recruiting | Tanabe Pharma Corporation | 344 | 2026-10-21 | 2026-11-12 |
| A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) V503, Placebo - Papillomavirus Infections | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 930 | 2026-10-10 | 2026-10-22 |
| Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts Intralesional Acyclovir, Intralesional Zinc Sulphate - Warts, Plantar Warts | Phase 3 | Not yet recruiting | Assiut University | 76 | 2026-10-01 | 2026-09-29 |
| Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster - Human Papillomavirus (HPV) Infection | Phase 3 | Not yet recruiting | PT Bio Farma | 266 | 2026-10-01 | 2026-09-17 |
| Study Interchangeability Hep-B Vaccine Administered at Birth Dose In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | PT Bio Farma | 270 | 2026-10-01 | 2026-10-02 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml), Rectal swab for ESBL-E and microbiota (Eswab), Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) - Neisseria Gonorrhoeae (Ng) Infections | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 360 | 2026-09-01 | 2026-06-22 |
| Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Pegylated liposomal doxorubicin, Paclitaxel - Kaposi Sarcoma, HIV-1-infection | Phase 3 | Not yet recruiting | AIDS Malignancy Consortium | 130 | 2026-09-01 | 2026-01-23 |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Early Corticosteroids in Severe Influenza Pneumonia Dexametasone, Sodium chloride 0.9% (placebo) - Severe Influenza, Intensive Care (ICU) | Phase 3 | Not yet recruiting | Centre Hospitalier Régional Metz-Thionville | 544 | 2026-09-01 | 2026-08-28 |
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC) - HIV Infections | Phase 3 | Recruiting | ViiV Healthcare | 197 | 2026-07-21 | 2026-11-13 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections | Phase 3 | Recruiting | Gilead Sciences | 590 | 2026-07-14 | 2026-08-14 |
| 500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection ceftriaxone 500-mg, ceftriaxone 1000-mg - Gonorrhea Infection | Phase 3 | Recruiting | National Taiwan University Hospital | 400 | 2026-07-01 | 2026-07-17 |
| Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B GST-HG141 - Chronic Hepatitis b | Phase 3 | Not yet recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 576 | 2026-06-26 | 2026-05-14 |
Showing 20 of 1558. Sign in to see all of them.
HIV Infections (600) · Hepatitis C (284) · Acquired Immunodeficiency Syndrome (269) · Hepatitis C, Chronic (201) · Hepatitis B (195) · Papillomavirus Infections (101) · Hepatitis B, Chronic (85) · Tetanus (58) · Diphtheria (57) · Whooping Cough (48) · Haemophilus Infections (47) · Infections (46) · Sexually Transmitted Diseases (45) · Uterine Cervical Neoplasms (45)
Infections (1512) · Virus Diseases (1447) · Blood-Borne Infections (1333) · RNA Virus Infections (1139) · Urogenital Diseases (901) · Genital Diseases (892) · Sexually Transmitted Diseases (847) · Sexually Transmitted Diseases, Viral (847) · Immune System Diseases (728) · Lentivirus Infections (718) · Retroviridae Infections (718) · Immunologic Deficiency Syndromes (717) · Digestive System Diseases (662) · Hepatitis, Viral, Human (641)
Ribavirin (202) · peginterferon alfa-2a (101) · Lamivudine (84) · Ritonavir (76) · Tenofovir (76) · Zidovudine (67) · efavirenz (62) · peginterferon alfa-2b (61) · Sofosbuvir (49) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (48) · Lopinavir (39) · Nevirapine (36) · Raltegravir Potassium (32) · abacavir (32) · daclatasvir (32)
Merck Sharp & Dohme LLC (120) · GlaxoSmithKline (114) · National Institute of Allergy and Infectious Diseases (NIAID) (109) · Gilead Sciences (76) · Bristol-Myers Squibb (60) · ViiV Healthcare (51) · AbbVie (48) · French National Agency for Research on AIDS and Viral Hepatitis (35) · Hoffmann-La Roche (30) · Boehringer Ingelheim (24) · Sanofi Pasteur, a Sanofi Company (23) · ANRS, Emerging Infectious Diseases (19) · Glaxo Wellcome (17) · Centers for Disease Control and Prevention (11) · Harvard School of Public Health (HSPH) (11)
United States (590) · Canada (233) · France (217) · Spain (196) · Germany (173) · Puerto Rico (167) · United Kingdom (167) · Italy (150) · Australia (134) · Belgium (123) · South Africa (118) · Thailand (106) · China (96) · Russia (90) · Brazil (85)
Connie Celum, MD, MPH (5) · Feinberg J (5)
PMID 41276263, PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 27422279, PMID 29377566, PMID 29404492, PMID 19935017, PMID 28193518, PMID 32184277, PMID 39324693, PMID 25040192, PMID 25583164, PMID 26743093, PMID 27847279, PMID 30868245, PMID 33901188, PMID 35174470, PMID 18657709, PMID 19236277, PMID 19236279, PMID 19571722, PMID 24979445, PMID 25424785, PMID 25445400, PMID 25992639, PMID 26947564, PMID 27553375, PMID 29074187, PMID 29211620, PMID 29767684, PMID 30982556, PMID 31824976, PMID 32829410, PMID 35149535, PMID 35508986, PMID 36740893, PMID 37452174, PMID 38160309, PMID 39052748, PMID 39101506, PMID 41166720, PMID 16890833, PMID 17716936, PMID 18532873, PMID 18832244, PMID 18832245
2014 (33), 2015 (29), 2009 (15), 2016 (13), 2004 (11), 2008 (10), 2017 (10), 2005 (8), 2019 (7), 2025 (4), U01CA121947 (4), 2023 (3), U01AI068636 (3), U01DK082843 (3), U01DK082864 (3)